open access

https://doi.org/10.14943/doctoral.r6905

https://hdl.handle.net/2115/56321

血管新生阻害療法のための新規標的分子の同定

英語

antiangiogenic therapy

2014-03-25

Hokkaido University

46

Targeting tumor angiogenesis is an established strategy for cancer therapy. Molecular markers that can distinguish between physiological and pathological angiogenesis are required to develop more effective and safer approaches for cancer treatment, because angiogenesis is not limited to pathological conditions such as cancer. To identify such molecules, we examined the gene expression profiles of murine tumor endothelial cells (mTECs) and normal endothelial cells (mNECs) by DNA microarray analysis followed by quantitative reverse transcription-polymerase chain reaction analysis. We identified 131 genes that were differentially upregulated in mTECs. Functional analysis using siRNA-mediated gene silencing revealed five novel TEC markers that were involved in the proliferation or migration of mTECs. The expression of DEF6 and TMEM176B was upregulated in tumor vessels of human renal cell carcinoma(RCC) specimens, suggesting that they are potential targets for antiangiogenic intervention for RCC. Comparative gene expression analysis revealed molecular differences between TECs and NECs and identified novel TEC markers that may be exploited to target tumor angiogenesis for cancer treatment.

2014-03-25

乙第6905号

博士(歯学)

(主査) 教授 進藤 正信, 特任准教授 樋田 京子, 教授 田村 正人

歯学研究科

博士論文

Version of Record